FullText URL s12885-017-3295-4.pdf
Author Yokota, T.| Ogawa, T.| Takahashi, S.| Okami, K.| Fujii, T.| Tanaka, K.| Iwae, S.| Ota, I.| Ueda, T.| Monden, N.| Matsuura, K.| Kojima, H.| Ueda, S.| Sasaki, K.| Fujimoto, Y.| Hasegawa, Y.| Beppu, T.| Nishimori, Hisakazu| Hirano, S.| Naka, Y.| Matsushima, Y.| Fujii, M.| Tahara, M.|
Abstract BACKGROUND: Recent preclinical and phase I studies have reported that rebamipide decreased the severity of chemoradiotherapy-induced oral mucositis in patients with oral cancer. This placebo-controlled randomized phase II study assessed the clinical benefit of rebamipide in reducing the incidence of severe chemoradiotherapy-induced oral mucositis in patients with head and neck cancer (HNC). METHODS: Patients aged 20-75 years with HNC who were scheduled to receive chemoradiotherapy were enrolled. Patients were randomized to receive rebamipide 2% liquid, rebamipide 4% liquid, or placebo. The primary endpoint was the incidence of grade ≥ 3 oral mucositis determined by clinical examination and assessed by central review according to the Common Terminology Criteria of Adverse Events version 3.0. Secondary endpoints were the time to onset of grade ≥ 3 oral mucositis and the incidence of functional impairment (grade ≥ 3) based on the evaluation by the Oral Mucositis Evaluation Committee. RESULTS: From April 2014 to August 2015, 97 patients with HNC were enrolled, of whom 94 received treatment. The incidence of grade ≥ 3 oral mucositis was 29% and 25% in the rebamipide 2% and 4% groups, respectively, compared with 39% in the placebo group. The proportion of patients who did not develop grade ≥ 3 oral mucositis by day 50 of treatment was 57.9% in the placebo group, whereas the proportion was 68.0% in the rebamipide 2% group and 71.3% in the rebamipide 4% group. The incidences of adverse events potentially related to the study drug were 16%, 26%, and 13% in the placebo, rebamipide 2%, and rebamipide 4% groups, respectively. There was no significant difference in treatment compliance among the groups. CONCLUSIONS: The present phase II study suggests that mouth washing with rebamipide may be effective and safe for patients with HNC receiving chemoradiotherapy, and 4% liquid is the optimal dose of rebamipide. TRIAL REGISTRATION: ClinicalTrials.gov under the identifier NCT02085460 (the date of trial registration: March 11, 2014).
Keywords Chemoradiotherapy Head and neck cancer Oral mucositis Placebo-controlled Randomized Rebamipide liquid
Published Date 2017-05-05
Publication Title BMC cancer
Volume volume17
Issue issue1
Publisher BioMed Central
Start Page 314
End Page 322
ISSN 1471-2407
NCID AA12034763
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja
File Version publisher
PubMed ID 28476132
DOI 10.1186/s12885-017-3295-4
Web of Sience KeyUT 000401614700001
Related Url https://doi.org/10.1186/s12885-017-3295-4
FullText URL K0005304 other1.pdf
Author Igawa, Takuro| Sato, Yasuharu| Takata, Katsuyoshi| Iwaki, Noriko| Tanaka, Takehiro| Asano, Naoko| Maeda, Yoshinobu| Orita, Yorihisa| Nakamura, Naoya| Nakamura, Shigeo| Yoshino, Tadashi|
Abstract  D cyclins positively regulate the cell cycle and mediate the pathogenesis of some lymphomas. Cyclin D1 overexpression is the hallmark of mantle cell lymphoma, whereas cyclins D2 and D3 are reportedly not as specific to certain lymphomas as cyclin D1. In this study, cyclin D2 was found to be overexpressed in 98% of de novo CD5-positive diffuse large B-cell lymphomas (DLBCLs) (50/51) and in 28% of CD5-negative DLBCLs (14/51). A statistically significant difference was observed between these two groups (p<0.0001). In contrast, no statistical difference was found in the cyclin D3 expression between CD5-positive (18/51) and CD5-negative (24/51) DLBCLs (p=0.23). Based on these findings, cyclin D2 is therefore considered to be closely associated with de novo CD5-positive DLBCLs. This insight may be useful for overcoming the inferior survival of this aggressive lymphoma.
Keywords Cyclin D2 CD5 Diffuse large B-cell lymphoma
Note 学位審査副論文
Published Date 2013-05-15
Publication Title Diagnostic Pathology
Volume volume8
Publisher BioMed Central
Start Page 81
ISSN 1746-1596
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja
File Version publisher
PubMed ID 23675804
DOI 10.1186/1746-1596-8-81
Web of Sience KeyUT 000319266300002
Related Url https://doi.org/10.1186/1746-1596-8-81 http://ousar.lib.okayama-u.ac.jp/54287
Author Takahashi, Shunichi| Tamashiro, Ayumu| Sakihama, Yasuko| Yamamoto, Yasusi| Kawamitsu, Yoshinobu| Yamasaki, Hideo|
Published Date 2002-04-02
Publication Title BMC Plant Biology
Volume volume2
Content Type Journal Article
Author Moritani, Norifumi H| Kubota, Satoshi| Sugahara, Toshio| Takigawa, Masaharu|
Published Date 2005-04-15
Publication Title Cell Communication and Signaling
Volume volume3
Issue issue1
Content Type Journal Article
Author Asano, Masahiro| Kubota, Satoshi| Nakanishi, Tohru| Nishida, Takashi| Yamaai, Tomoichiro| Yosimichi, Gen| Ohyama, Kazumi| Sugimoto, Tomosada| Murayama, Yoji| Takigawa, Masaharu|
Published Date 2005-10-05
Publication Title Cell Communication and Signaling
Volume volume3
Issue issue1
Content Type Journal Article
Author Nakai, Yukie| Milgrom, Peter| Yoshida, Toshiko| Ishihara, Chikako| Shimono, Tsutomu|
Published Date 2005-8-23
Publication Title BMC Medical Research Methodology
Volume volume5
Content Type Journal Article
Author Kawai, Mariko| Bessho, Kazuhisa| Maruyama, Hiroki| Miyazaki, Jun-ichi| Yamamoto, Toshio|
Published Date 2006-08-03
Publication Title BMC Musculoskeletal Disorders
Volume volume7
Content Type Journal Article
Author Uchida, Naohiko| Ujike, Hiroshi| Nakata, Kenji| Takaki, Manabu| Nomura, Akira| Katsu, Takeshi| Tanaka, Yuji| Imamura, Takaki| Sakai, Ayumu| Kuroda, Shigetoshi|
Published Date 2003-10-21
Publication Title BMC Psychiatry
Volume volume3
Content Type Journal Article
Author Matsumoto, Eiji| Nakatsuka, Harushige| Nouso, Kazuhiro| Nakamura, Shin-ichiro| Suzuki, Mayumi| Kobayashi, Yoshiyuki| Uemura, Masayuki| Sato, Syuichiro| Sato, Ei-ichiro| Yokoyama, Junko| Tsuboi, Sou| Tanaka, Hironori| Takuma, Yoshitake| Fujikawa, Tatsuya| Shiratori, Yasushi|
Published Date 2004-01-14
Publication Title Comparative Hepatology
Volume volume3
Content Type Journal Article
Author Altundag, Kadri| Altundag, Ozden| Gunduz, Mehmet|
Published Date 2004-06-15
Publication Title Breast Cancer Research
Volume volume6
Issue issue4
Content Type Journal Article
Author Tsujita-Kyutoku, Miki| Yuri, Takashi| Danbara, Naoyuki| Senzaki, Hideto| Kiyozuka, Yasuhiko| Uehara, Norihisa| Takada, Hideho| Hada, Takahiko| Miyazawa, Teruo| Ogawa, Yutaka| Tsubura, Airo|
Published Date 2004-04-26
Publication Title Breast Cancer Research
Volume volume6
Issue issue4
Content Type Journal Article
Author Hanafusa, Tadashi| Shinji, Toshiyuki| Shiraha, Hidenori| Nouso, Kazuhiro| Iwasaki, Yoshiaki| Yumoto, Eichiro| Ono, Toshiro| Koide, Norio|
Published Date 2005-01-20
Publication Title BMC Cancer
Volume volume5
Content Type Journal Article